Cancer Therapies and Biology Group, Centre of Research Excellence in Brain Tumours, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.
Tumour Targeting Program, Olivia Newton-John Cancer Wellness and Research Centre, Austin Hospital, Heidelberg, Melbourne, Australia.
Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1089-1102. doi: 10.1080/14712598.2023.2282729. Epub 2023 Dec 15.
Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these tumors.
This review will cover all the key classes of ADCs which have been tested in primary brain tumors, including commentary on the major trials to date. The efficacy of these trials, as well as their limitations, will put in context of the overall landscape of drug development in brain tumors. Importantly, this review will summarize key learnings and insights from these trials that help provide the basis for rational ways in which these drugs can be effectively and appropriate developed for patients with primary brain tumors.
ADC development in brain tumors has occurred in two major phases to date. Key learnings from previous trials provide a strong rationale for the continued development of these drugs for primary brain tumors. However, the unique biology of these tumors requires development strategies specifically tailored to maximize their optimal development.
抗体药物偶联物（ADC）现已成为许多癌症的一种经过验证的治疗类别，它将高特异性靶向与高效有效载荷的效力结合在一起。本综述总结了 ADC 在脑肿瘤中的应用经验，并探讨了它们在这些肿瘤中应用的未来途径。
本综述将涵盖所有已在原发性脑肿瘤中测试过的 ADC 主要类别，包括对迄今为止主要试验的评论。这些试验的疗效及其局限性将与脑肿瘤药物开发的整体格局联系起来。重要的是，本综述将总结这些试验中的关键经验教训和见解，为合理开发这些药物为原发性脑肿瘤患者提供依据。
迄今为止，ADC 在脑肿瘤中的开发经历了两个主要阶段。来自先前试验的关键经验为这些药物在原发性脑肿瘤中的持续开发提供了强有力的依据。然而，这些肿瘤的独特生物学特性需要专门制定开发策略，以最大限度地发挥其最佳开发效果。
